Inclusion Criteria:  Patients who are confirmed to have COVID-19 clinically, radiologically and PCR Age above 18 years old Informed written consent  Exclusion Criteria:  History of hypersensitivity to colchicine Pregnancy or breastfeeding women. Patients with severe renal impairment (creatinine clearance (CCL) <30 mL / min) Patients with severe hepatic impairment (AST or ALT> 5 times the normal limits in International Units (ULN) Patients with blood dyscrasias, neutrophils <1.000 / mmc or platelets <50.000 / mmc Patients with history of severe cardiac insufficiency Patients with history of pulmonary fibrosis Severe diarrhoea or bowel diverticulitis, or perforation Patients who cannot take oral therapy Patients already in ICU or requiring mechanical ventilation Patients already enrolled in other clinical trials Patients with taking P-glycoprotein inhibitor (e.g. ciclosporin, verapamil or quinidine) or a CYP3A4 inhibitor (e.g. ritonavir, remdesivir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketaconazole) or Tocilizumab